Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.

Alopecia areata is an autoimmune disease with genetic links, treatable with certain medications, and can affect mental health.

This article discusses various potential health benefits and increasing global interest in astaxanthin but presents no new clinical results, though ongoing trials are exploring its effects on chronic diseases and other conditions.

This review discusses the current role and challenges of compounding in dermatology without presenting new research results; the authors suggest its resurgence in practice despite pharmaceutical alternatives.

This review covers drug repurposing patent applications from April to June 2021, detailing potential new therapeutic uses for existing medications, but reports no new clinical results; the authors highlight novel treatment possibilities and suggest further research.

This study identified significant patient frustration with limited access to treatments for alopecia areata in Germany, exacerbated by the absence of health insurance reimbursement for necessary medications.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

This review focuses on the immunologic-based skin conditions that can result from β-blocker use, emphasizing potential adverse dermatologic effects rather than their therapeutic benefits.

This review suggests that mesenchymal stem cells' therapeutic effects might be due to bioactive substances they release, rather than the cells themselves, highlighting the potential of the MSC secretome as a novel, cell-free therapeutic approach.

Use the least toxic, most specific treatments for skin diseases, considering side effects and individual patient needs.

This article reviews stress-related skin reactions, psychodermatology, and neuropsychiatric skin manifestations, and reports no new clinical results.

This review discusses the various potential causes of hair loss in patients with inflammatory bowel disease, including telogen effluvium from disease flares, but provides no prevalence data; the authors outline a practical assessment and management approach.

This article discusses various hair diseases and emphasizes their significant impact despite affecting a small area, but does not report new clinical findings.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

This pharmacovigilance study identified 19 drugs with high potential risk for causing male infertility, including hormonal agents, antineoplastic drugs, and antidepressants, emphasizing the need for fertility counseling and possible sperm cryopreservation in reproductive-age males before using such treatments.

This study found that minor ginseng saponin F2 may promote hair growth more effectively than finasteride by enhancing anagen induction and modulating the Wnt signaling pathway in cell and mouse models.

This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.

In this review, researchers detail how immunosenescence and chronic neuroinflammation contribute to Parkinson's disease progression, exploring potential therapeutic strategies targeting this axis, such as senolytic agents and immune rejuvenation, while highlighting associated challenges and future research needs.

This review suggests that brassinosteroids may have similar biological activities in both plants and other organisms, prompting further exploration of steroid regulation mechanisms across different life forms.

The document describes skin diseases affecting the outer ear in dogs and cats, their spread to other body parts, and treatment options.

This review examines the use of microneedles for treating alopecia areata, highlighting their ability to enhance drug delivery through the skin by bypassing the outer barrier and promoting hair growth with minimal invasiveness.

This study found that coadministration of pimecrolimus may interfere with the therapeutic efficacy of mesenchymal stem cell therapy in atopic dermatitis.

A woman's complete hair loss condition improved after recovering from COVID-19.

This study proposes that the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia may contribute to poorer COVID-19 prognosis in males.

This review explores the potential of cell-mediated drug delivery systems in dermatology, highlighting their ability to target inflamed or diseased skin while discussing applications in diseases like atopic dermatitis and melanoma, along with challenges such as immunogenicity and manufacturing.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This article reviews TNF-α inhibitor-induced alopecia, identifying various types of hair loss such as severe alopecia areata and scarring alopecia, and calls for more controlled studies to better understand this adverse effect.

This paper reviews strategies to enhance the effectiveness of topical drug delivery by addressing skin barrier challenges, optimizing drug delivery systems, and personalizing treatment approaches, highlighting both current advancements and limitations in the field.

This review discusses the increasing reports of rare cutaneous side effects from topical imiquimod, aiming to inform physicians and dermatologists about its potential adverse effects as its use expands.